Connect with us

Hi, what are you looking for?

Nasdaq:VYNT

Vyant Bio Announces Participation at the 2022 CDKL5 Forum

#Vyant #Bio #Announces #Participation #CDKL5 #Forum

Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD)

CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning to identify novel therapeutic candidates for neurodevelopmental and neurodegenerative disorders. Today, Vyant Bio announced their participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7th and 8th, 2022, in Boston, MA through platform and poster presentations. In addition, Vyant Bio will participate in a CDKL5 deficiency disorder scientific workshop on Monday October 31st from 1-4 pm EDT and will present an industry perspective for the best practices for the use of human induced pluripotent stem cell (iPSC) derived brain organoids in drug discovery research.

Details for the platform talk and poster presentation include:

Title: High-throughput functional screening to develop novel therapies for CDKL5-deficiency disorder using human iPSC-derived cortical organoids
Authors: Matthew V. Green, Tori Alstat, Huda Ahmed, Kendra Prum, Cassiano Carromeu, Andrew LaCroix, Robert T. Fremeau, Jr.
Session: Molecular and Cellular Function
Session Date / Time: November 7, 11:35 am EDT

ABOUT CDKL5

CDKL5 stands for cyclin-dependent kinase-like 5, a protein whose gene is located on the X chromosome. The CDKL5 gene provides instructions for making a protein that is essential in forming the connections for normal brain development, with mutations causing a deficiency in the protein level. Mutations in the gene are usually spontaneous ‘de novo’ occurrences, rather than inherited….

Read on GNW: Vyant Bio Announces Participation at the 2022 CDKL5 Forum

You May Also Like

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...